Erik van Werkhoven
Erik van Werkhoven
Johns Hopkins Bloomberg School of Public Health
Geverifieerd e-mailadres voor
Geciteerd door
Geciteerd door
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ...
The Lancet Oncology 16 (6), 630-637, 2015
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
S Leijen, SA Burgers, P Baas, D Pluim, M Tibben, E van Werkhoven, ...
Investigational new drugs 33 (1), 201-214, 2015
Angiotensin II–receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial
AH Boekhout, JA Gietema, BM Kerklaan, ED van Werkhoven, R Altena, ...
JAMA oncology 2 (8), 1030-1037, 2016
Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival
MC van Harten, FJP Hoebers, KW Kross, ED van Werkhoven, ...
Oral oncology 51 (3), 272-278, 2015
Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically …
NM Graafland, W Lam, JAP Leijte, T Yap, MPW Gallee, C Corbishley, ...
European urology 58 (5), 742-747, 2010
Prognostic significance of extranodal extension in patients with pathological node positive penile carcinoma
NM Graafland, HH van Boven, E van Werkhoven, LMF Moonen, ...
The Journal of urology 184 (4), 1347-1353, 2010
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy
BB Koolen, MV Peeters, J Wesseling, EH Lips, WV Vogel, TS Aukema, ...
European journal of nuclear medicine and molecular imaging 39 (12), 1830-1838, 2012
Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months
S Leijen, RMJM van Geel, GS Sonke, D de Jong, EH Rosenberg, ...
Journal of Clinical Oncology 34 (36), 4354-4361, 2016
Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome
RS Djajadiningrat, ES Jordanova, BK Kroon, E van Werkhoven, J de Jong, ...
The Journal of urology 193 (2), 526-531, 2015
Comparison of the value of nursing work environments in hospitals across different levels of patient risk
JH Silber, PR Rosenbaum, MD McHugh, JM Ludwig, HL Smith, ...
JAMA surgery 151 (6), 527-536, 2016
Comparison of the value of nursing work environments in hospitals across different levels of patient risk
JH Silber, PR Rosenbaum, MD McHugh, JM Ludwig, HL Smith, ...
JAMA surgery 151 (6), 527-536, 2016
Penile sparing surgery for penile cancer—does it affect survival?
RS Djajadiningrat, E van Werkhoven, W Meinhardt, BWG van Rhijn, ...
The Journal of urology 192 (1), 120-126, 2014
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial
AV Louie, E van Werkhoven, H Chen, EF Smit, MA Paul, J Widder, ...
Radiotherapy and Oncology 117 (1), 44-48, 2015
Contemporary management of regional nodes in penile cancer—improvement of survival?
RS Djajadiningrat, NM Graafland, E van Werkhoven, W Meinhardt, A Bex, ...
The Journal of urology 191 (1), 68-73, 2014
Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial
C Vrieling, E van Werkhoven, P Maingon, P Poortmans, C Weltens, ...
JAMA oncology 3 (1), 42-48, 2017
Association of genetic risk variants with attention-deficit/hyperactivity disorder trajectories in the general population
L Riglin, S Collishaw, AK Thapar, S Dalsgaard, K Langley, GD Smith, ...
Jama psychiatry 73 (12), 1285-1292, 2016
Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial
E van Werkhoven, G Hart, H van Tinteren, P Elkhuizen, L Collette, ...
Radiotherapy and Oncology 100 (1), 101-107, 2011
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ...
The Lancet Oncology 19 (11), 1459-1467, 2018
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ...
Nature medicine 25 (6), 920-928, 2019
Long-term risk of dementia in persons with schizophrenia: a Danish population-based cohort study
AR Ribe, TM Laursen, M Charles, W Katon, M Fenger-Grøn, D Davydow, ...
JAMA psychiatry 72 (11), 1095-1101, 2015
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20